← All indications
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Subtype terms (2)
More specific conditions that are subtypes of Precursor Cell Lymphoblastic Leukemia-Lymphoma in the MeSH hierarchy.
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
309 drugs (149 approved, 160 experimental)
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
68 drugs (39 approved, 29 experimental)
Drugs by status
Approved for this indication (17)
Phase 4 trials (32)
- sulfadoxine
- methylphenidate
- methotrexate
- prednisolone
- pyrimethamine
- rifampin
- 23-valent pneumococcal polysaccharide vaccine
- cladribine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- vincristine
- tioguanine
- ceftazidime
- Anti-thymocyte Globulin (Rabbit)
- ciprofloxacin
- sargramostim
- acetylcysteine
- simvastatin
- ifosfamide
- ursodeoxycholic acid
- hydrocortisone
- idarubicin
- cyclophosphamide
- prednisone
- naltrexone
- busulfan
- artesunate
- etoposide
- urea
- pneumococcal 13-valent conjugate vaccine
- Filgrastim
- +2 more
Phase 3 trials (59)
- haploidentical mononuclear cells
- atorvastatin
- cyclosporine
- treosulfan
- autologous umbilical cord blood
- pentoxifylline
- azacitidine
- levocarnitine
- calcium phosphate
- venetoclax
- muromonab cd3
- mesna
- dexrazoxane
- chlorhexidine
- allogeneic cord blood
- Olverembatinib
- treggraft
- sirolimus
- allogeneic hematopoietic stem cells
- enalapril
- baricitinib
- epirubicin
- honey
- carvedilol
- methylprednisolone
- blinatumomab
- thiotepa
- omacetaxine
- pentostatin
- bone marrow derived mesenchymal stem cells
- +29 more
Phase 2 trials (149)
- autologous regulatory t cells
- jcar015
- vcl-cb01
- tafasitamab
- cytokine-treated veto cells
- carboplatin
- pf-04878691
- vinblastine
- dfp-10917
- gemtuzumab ozogamicin
- cn201
- levetiracetam
- ofatumumab
- docosahexaenoic acid
- midostaurin
- selumetinib
- nicotinamide
- ic9/car.19/il15-transduced cb-nk cells
- idelalisib
- trametinib
- rasburicase
- tbi-1501
- aminopterin
- cd8+ t cells
- cd3+ teff cells
- wu-cart-007
- itacitinib
- letermovir
- lysergic acid diethylamide
- haplo-identical hematopoietic stem cells
- +119 more
Phase 1 trials (127)
- Lisaftoclax
- Raltitrexed
- anti-cd19-car cmv-specific t-lymphocytes
- nivolumab
- nogapendekin alfa inbakicept
- autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells
- gnc-038
- prgn-3007
- betamethasone
- gemcitabine
- belinostat
- birabresib
- in 111-dota-basiliximab
- allogeneic cd123car-cd28-cd3zeta-egfrt-expressing t-lymphocytes
- romidepsin
- clioquinol
- cta30x
- deferasirox
- zilovertamab vedotin
- bmf-500
- eagd t-cell
- imj995
- sting-dependent activators (stavs) loaded autologous leukemic cells
- briciclib
- thiscart19
- cd70 car-t cells
- azd4573
- ciclopirox
- bafetinib
- kw2449
- +97 more
Organizations
Organization Involved with Phase 4 Indications (54)
- Huizhou People's Central Hospital
- International BFM Study Group
- Huazhong University of Science and Technology
- Xiamen University
- St. Jude Children's Hospital
- Danish Cancer Society
- Aarhus University
- Medac
- European Organisation for Research and Treatment of Cancer
- Shandong University
- Dalhousie University
- Shandong Province Qianfoshan Hospital
- Fudan University
- Southeast University
- Government of Austria
- PETHEMA Foundation
- University of Arizona
- Soochow University
- Italian Association of Pediatric Hematology-Oncology
- Zhengzhou University
- Danish Child Cancer Foundation
- Shandong Provincial Hospital
- Nanjing Medical University
- Southern Medical University
- Grupo Argentinode Tratamiento
- University of Oxford
- Qingdao University
- Universidad Autonoma de Barcelona
- Sun Yat-Sen University
- Guangzhou Medical University
- +24 more
Organization Involved with Phase 3 Indications (148)
- IRCCS Ospedale, Rome, Italy
- University Hospital of Berlin
- Aamu Pediatric Cancer Foundation
- Kiadis Pharma
- National Institute of General Medical Sciences (NIGMS)
- McMaster University
- University of Washington
- Cohen Children's Medical Center of New York
- Baxalta
- University of Wisconsin
- Tufts University
- Azienda Ospedaliera San Gerardo di Monza
- People's Liberation Army of China
- Medical College of Wisconsin
- National Institutes of Health (NIH)
- China Medical University
- Xuzhou Medical University
- University of Barcelona
- Maine Children's Cancer Program
- University of Liege
- Mayo Clinic
- University of Rochester
- National University of Malaysia
- Incyte
- Istanbul University
- University of Western Australia
- University of London
- University of Milan
- The Swedish Childhood Cancer Foundation
- Ohio State University
- +118 more
Organization Involved with Phase 2 Indications (260)
- U.O. di Ematologia- Ospedale dell'Angelo - Mestre
- The Wayne D. Kuni and Joan E. Kuni Foundation
- Hospital Nossa Senhora da Conceicao
- Government of Singapore
- Fate Therapeutics
- Renato Melaragno
- Henan University of Traditional Chinese Medicine
- AZ Sint-Jan
- University of British Columbia
- University of Nebraska
- Polyphor Ltd.
- Callisto Pharmaceuticals
- Cardiff University
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- University of Regensburg
- University of Nice Sophia Antipolis
- AO GENERIUM
- Hospital Brigadeiro
- Gottfried Wilhelm Leibniz Universität Hannover
- Nanchang University
- Colorado Blood Cancer Institute
- Universidad Autonoma de Madrid
- Bambino Gesù Hospital and Research Institute
- Methodist Cancer Center, Houston, Texas
- University of Utah
- Washington University in St. Louis
- University of Chicago
- Celldex Therapeutics
- Seattle Genetics
- Hospital de Clinicias da UICAMP
- +230 more
Organization Involved with Phase 1 Indications (99)
- OncoEthix
- Hrain Biotechnology Co., Ltd.
- Sabz Biomedicals
- GenScript
- University of North Carolina at Chapel Hill
- University of Lille
- Chongqing Medical University
- Tehran University of Medical Science
- Orca Biosystems, Inc.
- University of Bordeaux
- Shanghai Longyao Biotechnology Inc., Ltd.
- Bio-Path Holdings, Inc.
- In8Bio
- Threshold Pharmaceuticals
- iCell Gene Therapeutics
- The First People's Hospital of Yunan Province
- University of Toulouse
- Wenzhou Medical University
- Shenzhen immune gene therapy research institute
- Pediatric Cancer Foundation
- Regimmune Inc.
- Cellectis S.A.
- Seyyed-alshohada hospital of Isfahan
- Exelixis
- William Lawrence and Blanche Hughes Foundation
- National Comprehensive Cancer Network
- KAEDI
- Texas Tech University
- Kunming Medical University
- MediGene
- +69 more
Organization Involved with Other Experimental Indications (13)
- University of Mississippi
- Children's Cancer Research Fund United States
- Thermo Fisher Scientific
- Hebei Yanda Ludaopei Hospital
- Russian Academy of Medical Sciences
- MDS Pharma
- West Virginia University
- Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon
- University of Southern Denmark
- Leukosite
- National Autonomous University of Mexico
- Roxane Laboratories
- American Society of Clinical Oncology